It was shown that SC13 combination therapy sensitized cancer cells to low-concentration paclitaxel treatment, which meant that the side effects of paclitaxel could be avoided, and targeting FEN1 may be a new strategy for tumor-targeted therapy of cervical cancer. The gene discussed is FEN1; the disease is neoplasm.